SC
IGMS

Steven Cohen’s IGM Biosciences IGMS Stock Holding History

Steven Cohen’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-27,246
Closed -$187K – 2158
2024
Q2 		$187K Buy
+27,246
New +$233K ﹤0.01% 1623
2023
Q2 		– Sell
-129,740
Closed -$1.78M – 2450
2023
Q1 		$1.78M Buy
+129,740
New +$2.68M 0.01% 1000

Other funds holding IGMS

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Steven Cohen's IGMS Position: Q3 2024 in Review

Steven Cohen sold out of IGM Biosciences (IGMS) in Q3 2024, closing a stake of 27,246 shares — an estimated $187K sold.

Steven Cohen first reported a position in IGMS in Q1 2023 and held it in 2 quarters. The position peaked at $1.78M in Q1 2023. 72 funds tracked by Wall St. Rank hold IGMS as of Q3 2024.

  • Steven Cohen reported no remaining IGM Biosciences position as of Q3 2024 after selling out during the quarter.
  • Steven Cohen sold 27,246 IGM Biosciences shares in Q3 2024, an estimated $187K.
  • Steven Cohen first reported a position in IGM Biosciences in Q1 2023 and held it in 2 quarters.
  • Steven Cohen's IGM Biosciences position peaked at $1.78M in Q1 2023.
  • 72 funds tracked by Wall St. Rank held IGM Biosciences as of Q3 2024.

Based on Point72 Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.